Journal
BMC WOMENS HEALTH
Volume 11, Issue -, Pages -Publisher
BMC
DOI: 10.1186/1472-6874-11-24
Keywords
lung function; menstrual cycle; sex hormones; asthma; cystic fibrosis; COPD
Funding
- GSK/CIHR
- Wyeth Pharmaceuticals
- Glaxo-Smith-Kline
- Astro-Zenecca
- Michael Smith Foundation for Health Research (MSFHR)
- Pfizer
Ask authors/readers for more resources
Background: The prevalence, morbidity, and mortality of inflammatory lung diseases such as asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) are increasing in women. There is a dearth of data on the biological mechanisms to explain such observations. However, some large epidemiologic studies suggest that lung function fluctuates during the menstrual cycle in female patients with airways disease but not in women without disease, suggesting that circulating estradiol and progesterone may be involved in this process. Discussion: In asthma, estradiol shuttles adaptive immunity towards the T(H)2 phenotype while in smokers estrogens may be involved in the generation of toxic intermediate metabolites in the airways of female smokers, which may be relevant in COPD pathogenesis. In CF, estradiol has been demonstrated to up-regulate MUC5B gene in human airway epithelial cells and inhibit chloride secretion in the airways. Progesterone may augment airway inflammation. Summary: Taken together, clinical and in-vivo data have demonstrated a sex-related difference in that females may be more susceptible to the pathogenesis of lung diseases. In this paper, we review the effect of female sex hormones in the context of these inflammatory airway diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available